DENTSPLY SIRONA Inc. (XRAY) Stock Score, Valuation & Financial Research
DENTSPLY SIRONA Inc. is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 21/100.
Quick answer for XRAY
DENTSPLY SIRONA Inc. currently has a Wall Street Score of 21/100. The stored market price is $10.46. Its financial score is 21/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What DENTSPLY SIRONA Inc. does
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishe
XRAY financial snapshot
- Wall Street Score:
- 21/100
- Current price:
- $10.46
- Market capitalization:
- $2.10B
- Revenue:
- $3.68B
- Net income:
- $-628.0M
- Free cash flow:
- $104.0M
- Cash:
- $190.0M
- Total debt:
- $2.33B
- EPS:
- -3.00
- Financial score:
- 21/100
- Valuation score:
- 0/100
- Revenue score:
- 14/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $104.0M, showing positive cash generation.
- The balance sheet shows $190.0M of cash versus $2.33B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 21/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research XRAY
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.